Next Article in Journal
The Role of Insulin Resistance/Hyperinsulinism on the Rising Trend of Thyroid and Adrenal Nodular Disease in the Current Environment
Next Article in Special Issue
Biochemical Assessment and Monitoring of Mitochondrial Disease
Previous Article in Journal
From Prenatal to Preimplantation Genetic Diagnosis of β-Thalassemia. Prevention Model in 8748 Cases: 40 Years of Single Center Experience
Previous Article in Special Issue
Biomarkers for Detecting Mitochondrial Disorders
Article

Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment

by 1,2,*, 1,3, 1 and 1,4,*
1
Neurometabolic Unit, National Hospital, Queen Square, London WC1N 3BG, UK
2
Department of Pharmacy and Biomolecular Science, Liverpool John Moores University, Byrom Street, Liverpool L3 5UA, UK
3
Institute of Medical Sciences, University of Aberdeen, Scotland AB24 3FX, UK
4
UCL Great Ormond Street Institute of Child Health, University College London, London WC1E 6BT, UK
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(2), 36; https://doi.org/10.3390/jcm7020036
Received: 1 February 2018 / Revised: 15 February 2018 / Accepted: 18 February 2018 / Published: 20 February 2018
Objectives: Evidence of mitochondrial respiratory chain (MRC) dysfunction and oxidative stress has been implicated in the pathophysiology of multiple sclerosis (MS). However, at present, there is no reliable low invasive surrogate available to evaluate mitochondrial function in these patients. In view of the particular sensitivity of MRC complex IV to oxidative stress, the aim of this study was to assess blood mononuclear cell (BMNC) MRC complex IV activity in MS patients and compare these results to age matched controls and MS patients on β-interferon treatment. Methods: Spectrophotometric enzyme assay was employed to measure MRC complex IV activity in blood mononuclear cell obtained multiple sclerosis patients and aged matched controls. Results: MRC Complex IV activity was found to be significantly decreased (p < 0.05) in MS patients (2.1 ± 0.8 k/nmol × 10−3; mean ± SD] when compared to the controls (7.2 ± 2.3 k/nmol × 10−3). Complex IV activity in MS patients on β-interferon (4.9 ± 1.5 k/nmol × 10−3) was not found to be significantly different from that of the controls. Conclusions: This study has indicated evidence of peripheral MRC complex IV deficiency in MS patients and has highlighted the potential utility of BMNCs as a potential means to evaluate mitochondrial function in this disorder. Furthermore, the reported improvement of complex IV activity may provide novel insights into the mode(s) of action of β-interferon. View Full-Text
Keywords: mitochondrial respiratory chain; complex IV; blood mononuclear cells; multiple sclerosis; β-Interferon mitochondrial respiratory chain; complex IV; blood mononuclear cells; multiple sclerosis; β-Interferon
Show Figures

Figure 1

MDPI and ACS Style

Hargreaves, I.; Mody, N.; Land, J.; Heales, S. Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment. J. Clin. Med. 2018, 7, 36. https://doi.org/10.3390/jcm7020036

AMA Style

Hargreaves I, Mody N, Land J, Heales S. Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment. Journal of Clinical Medicine. 2018; 7(2):36. https://doi.org/10.3390/jcm7020036

Chicago/Turabian Style

Hargreaves, Iain, Nimesh Mody, John Land, and Simon Heales. 2018. "Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity is Decreased in Multiple Sclerosis Patients: Effects of β-Interferon Treatment" Journal of Clinical Medicine 7, no. 2: 36. https://doi.org/10.3390/jcm7020036

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop